Chemotherapy response evaluation in metastatic colorectal cancer with FDG PET/CT and CT scans

Anticancer Research

Volumn 29, Issue 7, 2009, Pages 2563-2568

  Monteil, J ^a   Mahmoudi, N ^a   Leobon, S ^a   Roudaut, P Y ^a   El Badaoui, A ^a   Verbeke, S ^a   Venat Bouvet, L ^a   Martin, J ^a   Le Brun Ly, V ^a   Lavau Denes, S ^a   Maubon, A ^a   Bouillet, P ^a   Pouquet, M ^a   Vandroux, J C ^a   Tubiana Mathieu, Nicole ^a,b  

^a LIMOGES UNIVERSITY HOSPITAL   (France)

^b DUPUYTREN UNIVERSITY HOSPITAL   (France)

Author keywords

18F FDG; CT scan; Metastatic colorectal cancer; PET CT; Therapeutic assessment

Indexed keywords

CA 19-9 ANTIGEN; DIPEPTIDYL CARBOXYPEPTIDASE; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; HUMAN; LIVER METASTASIS; MALE; METABOLIC RATE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 69249181347     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Kelloff GJ, Hoffman JM, Johnson B, Scher HI, Siegel BA, Cheng EY, Cheson BD, O'Shaughnessy J, Guyton KZ, Mankoff DA, Shankar L, Larson SM, Sigman CC, Schilsky RL and Sullivan DC: Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 11: 2785-2808, 2005. (Pubitemid 40525178)
2. 18F-fluorodeoxyglucose positron-emission tomography in the detection of liver metastases. Ann Oncol 9: 397-401, 1998. (Pubitemid 28273032)
3. 18F-EDG positron-emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg 178: 282-287, 1999.
4. Ruers TJ, Langenhoff BS, Neeleman N, Jager GJ, Strijk S, Wobbes T, Corstens FH and Oyen WJ: Value of positron-emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J Clin Oncol 20: 388-395, 2002. (Pubitemid 34072520)
5. Hillner BE, Siegel BA, Liu D, Shields AF, Gareen IF, Hanna L, Stine SH and Coleman RE: Impact of positron-emission tomography/computed tomography and positron-emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. J Clin Oncol 26: 2155-2161, 2008.
6. Weber WA and Figlin R: Monitoring cancer treatment with PET/CT: does it make a difference? J Nucl Med 48(Suppl 1): 36S-44S, 2007.
7. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, Pruim J and Price P: Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron-emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35: 1773-1782, 1999.
8. Hoekstra OS, Ossenkoppele GJ, Golding R, van Lingen A, Visser GW, Teule GJ and Huijgens PC: Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. J Nucl Med 34: 1706-1710, 1993. (Pubitemid 23295382)
9. Weber WA: Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med 46: 983-995, 2005.
10. 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 47: 1059-1066, 2006. (Pubitemid 46939960)
11. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
12. Jaffe CC: Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol 24: 3245-3251, 2006.
13. Cachin F, Kelly A and Maublant J: Evaluation of the therapeutic response: role of isotopic imaging. Bull Cancer 93: 1191-1199, 2006 (in French). (Pubitemid 46064054)
14. Thie JA: Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med 45: 1431-1434, 2004.
15. Stahl A, Ott K, Schwaiger M and Weber WA: Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET. Eur J Nucl Med Mol Imaging 31: 1471-1478, 2004. (Pubitemid 39592766)
16. 18F-FDG PET. Methods Mol Med 111: 417-440, 2005.
17. Boucher L, Rodrigue S, Lecomte R and Benard F: Respiratory gating for 3-dimensional PET of the thorax: feasibility and initial results. J Nucl Med 45: 214-219, 2004. (Pubitemid 47618639)
18. 18F- fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 94: 429-433, 1999. (Pubitemid 29323856)
19. Mac Manus MP, Hicks RJ, Matthews JP, McKenzie A, Rischin D, Salminen EK and Ball DL: Positron-emission tomography is superior to computed tomography scanning for response assessment after radical radiotherapy or chemoradiotherapy in patients with non-small cell lung cancer. J Clin Oncol 21: 1285-1292, 2003. (Pubitemid 46606405)
20. Guillem JG, Puig-La Calle J, Jr., Akhurst T, Tickoo S, Ruo L, Minsky BD, Gollub MJ, Klimstra DS, Mazumdar M, Paty PB, Macapinlac H, Yeung H, Saltz L, Finn RD, Erdi Y, Humm J, Cohen AM and Larson S: Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron-emission tomography. Dis Colon Rectum 43: 18-24, 2000. (Pubitemid 30056657)
21. Amthauer H, Denecke T, Rau B, Hildebrandt B, Hunerbein M, Ruf J, Schneider U, Gutberlet M, Schlag PM, Felix R and Wust P: Response prediction by FDG-PET after neoadjuvant radiochemotherapy and combined regional hyperthermia of rectal cancer: correlation with endorectal ultrasound and histopathology. Eur J Nucl Med Mol Imaging 31: 811-819, 2004. (Pubitemid 38758350)
22. de Geus-Oei LF, van Laarhoven HW, Visser EP, Hermsen R, van Hoorn BA, Kamm YJ, Krabbe PF, Corstens FH, Punt CJ and Oyen WJ: Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer. Ann Oncol 19: 348-352, 2008. (Pubitemid 351201718)
23. Lubezky N, Metser U, Geva R, Nakache R, Shmueli E, Klausner JM, Even-Sapir E, Figer A and Ben-Haim M: The role and limitations of 18-fluoro-2-deoxy-D-glucose positron-emission tomography (FDG-PET) scan and computerized tomography (CT) in restaging patients with hepatic colorectal metastases following neoadjuvant chemotherapy: comparison with operative and pathological findings. J Gastrointest Surg 11: 472-478, 2007.
24. Tan MC, Linehan DC, Hawkins WG, Siegel BA and Strasberg SM: Chemotherapy-induced normalization of FDG uptake by colorectal liver metastases does not usually indicate complete pathologic response. J Gastrointest Surg 11: 1112-1119, 2007.
25. Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA and Charnsangavej C: We should desist using RECIST, at least in GIST. J Clin Oncol 25: 1760-1764, 2007. (Pubitemid 46797958)
26. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA and Benjamin RS: Correlation of computed tomography and positron-emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25: 1753-1759, 2007. (Pubitemid 46797957)